To summarize, this important article describes a population-based, inception cohort of IBD patients and demonstrates that less than half of CD or UC patients in a community setting will require CS therapy. For those that do require CS, the short-term response is very good (only 16% of patients are CS-resistant); however, transitioning to an immunomodulator appears to be necessary to sustain a long-term response in CD, and possibly in UC.
|Original language||English (US)|
|Number of pages||2|
|Journal||Reviews in Gastroenterological Disorders|
|State||Published - Jan 1 2002|
ASJC Scopus subject areas